30 results about "ERYTHROCYTES AGGLUTINATION" patented technology

The invention provides methods for preparing pharmaceutical formulations for injection such that upon injection the formulation does not cause erythrocyte agglutination, hemolysis, and / or cell shrinkage. To prevent agglutination, a pharmaceutical formulation ready for injection needs to have a sufficient ionic strength. To prevent hemolysis or cell shrinkage, a pharmaceutical formulation ready for injection needs to be about isotonic with respect to plasma. The invention provides methods that prepare pharmaceutical formulations for injection that have both the sufficient ionic strength to prevent agglutination and the requisite tonicity to prevent significant hemolysis or cell dehydration or shrinkage. The present methods involve the use of sodium chloride solutions that are about 25 mM to about 150 mM for reconstituting lyophilized cakes (or other non-liquid pharmaceutical formulations) into solution or for diluting pharmaceutical formulation solutions.

The invention provides a mosquito repelling and antibacterial cellulose fiber containing wormwood components, the fiber, the content of chitosan-functional component composite particles is 9.0-9.3%, and the content of silicic acid composite colloid is 2.2-2.5%; The present invention also provides a preparation method of mosquito repellent and antibacterial cellulose fiber containing wormwood components, the preparation method comprising preparation of chitosan-functional component composite particles, preparation of silicic acid composite colloid, blending, spinning and forming. The fiber prepared by the present invention has a mosquito repellent rate of 99.5-99.8%; a bacteriostasis rate of 96.7-97.3% for Candida albicans; and a erythrocyte agglutination method for influenza A virus and influenza B virus, and the titers all reach 7 -8; the fiber prepared by the present invention, the content of chitosan-functional component composite particles is 9.1-9.3%, and the content of silicic acid composite colloid is 2.2-2.5%.

A cell analyzer and its erythrocyte agglutination alarm method and system, which measure the volume information of cells in a sample to be tested, identify cells whose volume information in the sample to be tested is greater than a preset volume threshold, obtain agglutinated red blood cell groups, and count the agglutinated red blood cell groups The number of cells was obtained to obtain the amount of erythrocyte agglutination. It is judged whether the amount of red blood cell agglutination is greater than the preset number threshold, and if the amount of red blood cell aggregation is greater than the number threshold, an alarm for red blood cell agglutination is performed. Since the agglutinated erythrocytes are identified directly according to the cell volume, it is not necessary to judge according to the content of specific components in the cells. Compared with the traditional erythrocyte agglutination alarm method, the alarm accuracy is improved, and it is simple and fast.

The invention discloses an attenuated strain and an inactivated vaccine of the Newcastle disease virus and application thereof, belonging to the field of separation and application of a Newcastle disease virus strain. The Newcastle disease virus attenuated strain (DL11 strain) is separated from chicken disease materials and has a microbe preservation number of CGMCC No. 7958. According to results of hemagglutination and hemagglutination inhibition tests, the separated virus strain is the Newcastle disease virus strain; and intravenous pathogenicity index determination tests prove that the virus strain is the Newcastle disease virus attenuated strain. The erythrocyte agglutination value and virus content in a semi-finished product of the separated Newcastle disease virus attenuated strain are both higher than standards prescribed in Veterinary Biological Product Regulations; and the separated Newcastle disease virus attenuated strain has low preparation cost and meets requirements for mass production. The inactivated vaccine prepared from the attenuated strain has high immune efficacy, can resist attack by a virulent strain and is applicable as a vaccine strain for prevention or diagnosis of the Newcastle disease virus.